Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus MEASURIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE D SINUS COLD versus MEASURIN.
ALEVE-D SINUS & COLD vs MEASURIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Measurin is an aspirin preparation that irreversibly inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin and thromboxane synthesis. This results in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
None Documented
None Documented
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
Plasma elimination half-life is 2-3 hours at low doses (antiplatelet) and increases to 15-30 hours at anti-inflammatory doses due to saturation of hepatic metabolism; clinical context: higher doses require longer dosing intervals to avoid accumulation.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid) accounts for >90% of elimination; minor biliary/fecal excretion (<5%) occurs.
Category C
Category C
NSAID/Decongestant Combination
NSAID